Open brianmackenna opened 4 years ago
Should we have methotrexatein this codelist? I think we should but question mark over oral / iv. I think we should include all preps.
We did talk about gold the other day as well? What was the outcome? I agree that MTX should be in list AND all preps included. A lot of primary care rheum patients have been moved from oral to parenteral haven't they?
Gold: No decision -> prescribing is here.
The use of methotrexate injections in primary care is regionally varied depending on shared care arrangements. I recall from MTX paper that Devon was quite well advanced with primary care prescribing but other places not so much. There's a risk of mis classification............ @ianjdouglas any thoughts on this?
This risk is with all DMARDs due to variation in shared care.
I think better to include all, knowing it's imperfect. As we're adjusting for DMARDs and stratifying on them, leaving them out will only increase misclassification. But we should discuss in limitations
When compiling a codelist for mycophenolate we decided to include mycophenolic acid - we should consider adding this to the grouped list of DMARDs
https://codelists.opensafely.org/codelist/opensafely/mycophenolate/30754455/
notebook for further discussion / checking https://github.com/ebmdatalab/immunosuppressant-covid-codelist-notebook/blob/master/notebooks/dmards.primary.care.ipynb